Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about FibroGen, Inc.
FibroGen, Inc. News
FibroGen, Inc. Quantitative Score
About FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FibroGen, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
FibroGen, Inc. Financials
Table Compare
Compare FGEN metrics with: | |||
|---|---|---|---|
Earnings & Growth | FGEN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | FGEN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | FGEN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | FGEN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
FibroGen, Inc. Income
FibroGen, Inc. Balance Sheet
FibroGen, Inc. Cash Flow
FibroGen, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Neutral |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
FibroGen, Inc. Executives
| Name | Role |
|---|---|
| Thane Wettig | Chief Executive Officer & Director |
| David DeLucia | Senior VP & CFO |
| John Alden | Corporate Secretary & General Counsel |
| Gaia Vasiliver-Shamis | Director of IR & Communications - LifeSci Advisors |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Thane Wettig | Chief Executive Officer & Director | Male | 1965 | 1.13M |
| David DeLucia | Senior VP & CFO | Male | 1989 | 597.54K |
| John Alden | Corporate Secretary & General Counsel | Male | -- | |
| Gaia Vasiliver-Shamis | Director of IR & Communications - LifeSci Advisors | Female | -- |
FibroGen, Inc. Insider Trades
| Date | 6 Dec |
| Name | DeLucia David |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 52 |
| Date | 6 Dec |
| Name | Wettig Thane |
| Role | CEO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 259 |
| Date | 13 Nov |
| Name | Wettig Thane |
| Role | CEO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 1000 |
| Date | 17 Nov |
| Name | Wettig Thane |
| Role | CEO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 2700 |
| Date | 6 Jun |
| Name | DeLucia David |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 51 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 6 Dec | DeLucia David | Chief Financial Officer | Disposed | F-InKind | 52 |
| 6 Dec | Wettig Thane | CEO | Disposed | F-InKind | 259 |
| 13 Nov | Wettig Thane | CEO | Acquired | P-Purchase | 1000 |
| 17 Nov | Wettig Thane | CEO | Acquired | P-Purchase | 2700 |
| 6 Jun | DeLucia David | Chief Financial Officer | Disposed | F-InKind | 51 |